-
Clinical Drug Investigation 2010Mesalazine therapy for ulcerative colitis has been reported to be effective and safe. Rare cases of mesalazine-induced renal, pancreatic, myo-pericardial,...
Mesalazine therapy for ulcerative colitis has been reported to be effective and safe. Rare cases of mesalazine-induced renal, pancreatic, myo-pericardial, pleuro-pulmonary and haematological toxicity have been described separately. We report a case characterized by the simultaneous presence of fever, pericarditis, peripheral eosinophilia, eosinophilic pneumonia, anaemia and haematuria (together with proteinuria and leukocyturia) due to mesalazine treatment in a patient with ulcerative colitis. No clinical response had been obtained with corticosteroids and various antibacterial agents. When mesalazine treatment was suspended, all symptoms rapidly and totally disappeared, confirming the direct responsibility of this drug in causing these adverse events. We conclude that mesalazine can induce multi-organ hypersensitivity, which must always be considered as a possible adverse effect during treatment with this drug. To resolve this adverse event it is essential to discontinue mesalazine treatment.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Drug Hypersensitivity; Humans; Male; Mesalamine
PubMed: 20441247
DOI: 10.1007/BF03256911 -
The Medical Letter on Drugs and... Mar 2007
Topics: Administration, Oral; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Drug Administration Schedule; Drug Interactions; Humans; Mesalamine; Randomized Controlled Trials as Topic
PubMed: 17375030
DOI: No ID Found -
Alimentary Pharmacology & Therapeutics Sep 1999
Topics: Anti-Inflammatory Agents, Non-Steroidal; Delayed-Action Preparations; Humans; Hydrogen-Ion Concentration; Inflammatory Bowel Diseases; Mesalamine
PubMed: 10469474
DOI: 10.1046/j.1365-2036.1999.0612e.x -
Lancet (London, England) Nov 1997
Topics: Anti-Inflammatory Agents, Non-Steroidal; Humans; Inflammatory Bowel Diseases; Mesalamine
PubMed: 9357436
DOI: 10.1016/S0140-6736(05)62495-6 -
Expert Opinion on Drug Metabolism &... Dec 2009Balsalazide is the newer 5-aminosalicylic acid (5-ASA) prodrug which releases active 5-ASA only into the colon with minimal systemic absorption. The onset of action of... (Review)
Review
Balsalazide is the newer 5-aminosalicylic acid (5-ASA) prodrug which releases active 5-ASA only into the colon with minimal systemic absorption. The onset of action of this drug is variable, and it may take at least some days to reach clinical effectiveness. Clinical studies found balsalazide faster than mesalazine in the induction of remission, but balsalazide has no benefit compared with mesalazine in preventing relapse in the population selected. However, the high number of pills to take may affect the adherence to the treatment. This 5-ASA prodrug may be effectively used also in patients unable to tolerate other mesalamine compounds for non-hypersensitivity reasons. The costs of balsalazide capsules seem to be lower for the health system, both considering total direct healthcare costs and better outcomes, compared with patients treated with oral mesalazine. Finally, there is also some recent evidence that balsalazide may be effectively used, in combination with probiotics, in treating acute uncomplicated diverticulitis is the colon.
Topics: Colitis, Ulcerative; Colonic Diseases; Gastrointestinal Agents; Humans; Mesalamine; Phenylhydrazines; Prodrugs; Treatment Outcome
PubMed: 19708827
DOI: 10.1517/17425250903228842 -
The American Journal of Gastroenterology Apr 2009
Topics: Anemia, Aplastic; Anti-Inflammatory Agents, Non-Steroidal; Antilymphocyte Serum; Crohn Disease; Diagnosis, Differential; Drug Therapy, Combination; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Immunosuppressive Agents; Mesalamine; Middle Aged; Recombinant Proteins; Risk Factors
PubMed: 19259075
DOI: 10.1038/ajg.2008.164 -
Renal Failure 20095-aminosalicylate compounds (mesalazine, sulfasalazine) are widely used in therapy of inflammatory bowel diseases. Mesalazine-induced interstitial nephritis is a rare...
5-aminosalicylate compounds (mesalazine, sulfasalazine) are widely used in therapy of inflammatory bowel diseases. Mesalazine-induced interstitial nephritis is a rare complication; however, the morbidity in an affected individual is high. Regular renal screening in patients treated with 5-aminosalicylate compounds is important. A 15-year-old boy with treated idiopathic proctocolitis, consequent mesalazine-induced nephritis, and a favorable response to corticotherapy is presented.
Topics: Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Humans; Male; Mesalamine; Nephritis, Interstitial; Proctocolitis
PubMed: 19212915
DOI: 10.1080/08860220802595922 -
Phytomedicine : International Journal... Dec 2022Qingchang Wenzhong Decoction (QCWZD), a chinese herbal prescription, is widely used for ulcerative colitis (UC). Nevertheless, the active ingredients and mechanism of...
BACKGROUND
Qingchang Wenzhong Decoction (QCWZD), a chinese herbal prescription, is widely used for ulcerative colitis (UC). Nevertheless, the active ingredients and mechanism of QCWZD in UC have not yet been explained clearly.
PURPOSE
This research focuses on the identification of the effective ingredients of QCWZD and the prediction and verification of their potential targets.
METHODS
The UC mice were established by adding 3.0% dextran sulfate sodium (DSS) to sterile water for one week. Concurrently, mice in the treatment group were gavage QCWZD or mesalazine. LC-MS analyzed the main components absorbed after QCWZD treatment, and network pharmacology predicted their possible targets. ELISA, qPCR, immunohistochemistry and immunofluorescence experiments were used to evaluate the colonic inflammation level and the intestinal barrier completeness. The percentage of Th17 and Treg lymphocytes was detected by flow cytometry.
RESULTS
After QCWZD treatment, twenty-seven compounds were identified from the serum. In addition, QCWZD treatment significantly reduced the increased myeloperoxidase (MPO) and inflammatory cell infiltration caused by DSS in the colonic. In addition, QCWZD can reduce the secretion of inflammatory factors in serum and promote the expression of mRNAs and proteins of occludin and ZO-1. Network pharmacology analysis indicated that inhibiting IL-6-STAT3 pathway may be necessary for QCWZD to treat UC. Flow cytometry analysis showed that QCWZD can restore the normal proportion of Th17 lymphocytes in UC mice. Mechanistically, QCWZD inhibited the phosphorylation of JAK2-STAT3 pathway, reducing the transcriptional activation of RORγT and IL-17A.
CONCLUSIONS
Overall, for the first time, our work revealed the components of QCWZD absorbed into blood, indicated that the effective ingredients of QCWZD may inhibit IL-6-STAT3 pathway and inhibit the differentiation of Th17 lymphocytes to reduce colon inflammation.
Topics: Animals; Colitis, Ulcerative; Colon; Dextran Sulfate; Disease Models, Animal; Inflammation; Interleukin-17; Interleukin-6; Mesalamine; Mice; Mice, Inbred C57BL; Nuclear Receptor Subfamily 1, Group F, Member 3; Occludin; Peroxidase; Th17 Cells; Water
PubMed: 36182798
DOI: 10.1016/j.phymed.2022.154460 -
BMJ Clinical Evidence Feb 2016Diverticula (mucosal outpouchings through the wall of the colon) are rare before the age of 40 years, after which prevalence increases steadily and reaches over 25% by... (Review)
Review
INTRODUCTION
Diverticula (mucosal outpouchings through the wall of the colon) are rare before the age of 40 years, after which prevalence increases steadily and reaches over 25% by 60 years. However, only 10% to 25% of affected people will develop symptoms such as lower abdominal pain. Recurrent symptoms are common, and 5% of people with diverticula eventually develop complications such as perforation, obstruction, haemorrhage, fistulae, or abscesses.
METHODS AND OUTCOMES
We conducted a systematic overview, aiming to answer the following clinical question: What are the effects of medical treatments for acute diverticulitis? We searched: Medline, Embase, The Cochrane Library, and other important databases up to August 2014 (Clinical Evidence overviews are updated periodically; please check our website for the most up-to-date version of this overview).
RESULTS
At this update, searching of electronic databases retrieved 193 studies. After deduplication and removal of conference abstracts, 75 records were screened for inclusion in the overview. Appraisal of titles and abstracts led to the exclusion of 37 studies and the further review of 38 full publications. Of the 38 full articles evaluated, four systematic reviews and one RCT were added at this update. We performed a GRADE evaluation for two PICO combinations
CONCLUSIONS
In this systematic overview, we categorised the efficacy for one comparison based on information about the effectiveness and safety of medical treatment (mesalazine, antibiotics [any] only) versus placebo or no treatment.
Topics: Acute Disease; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Diverticulitis; Humans; Mesalamine; Treatment Outcome
PubMed: 26854496
DOI: No ID Found -
Gastroenterologia Y Hepatologia Apr 2018
Topics: Adrenal Cortex Hormones; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Crohn Disease; Female; Fever; Fluid Therapy; Humans; Mesalamine; Middle Aged; Norepinephrine; Sacroiliitis
PubMed: 28431755
DOI: 10.1016/j.gastrohep.2017.03.009